About Akebia Therapeutics, Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142
Akebia Therapeutics, Inc News and around…
Latest news about Akebia Therapeutics, Inc (AKBA) common stock and company :
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 – November 7, 2021. Vadadustat is Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, a potential first-in-class product in the U.S.
Investors in Akebia Therapeutics Inc (AKBA) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AKBA options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unwilling to wait for catalysts, some investors threw these small-cap stocks into the garbage bin. But that doesn't mean they won't succeed. The post 7 Small-Cap Stocks to Buy From the Beat-Up Bargain Bin appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 180,000 shares of Akebia's common stock on September 30, 2021, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
A noted investment bank takes a dimmer view of the company's stock.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Investors in Akebia Therapeutics Inc (AKBA) saw new options begin trading this week, for the October 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AKBA options chain for the new October 15th contracts and identified one put and one call contract of particular interest.
Investors in Akebia Therapeutics Inc (AKBA) saw new options become available this week, for the January 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 141 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following schedule of investor conferences:
Investors eyeing a purchase of Akebia Therapeutics Inc (AKBA) stock, but cautious about paying the going market price of $2.50/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2022 put at the $2 strike, which has a bid at the time of this writing of 35 cents..
TheEuropean Commission (EC) has approvedFibroGen Inc(NASDAQ: FGEN) andAstellas Pharma's(OTC: ALPMF) ...
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn ...
AKBA earnings call for the period ending June 30, 2021.
Investors liked what they heard in the company's Q2 update.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones. The Company will host a conference call today, Thursday, August 5, 2021, at 9:00 a.m. Eastern Time.
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc.
LOS ANGELES, July 27, 2021--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc.
Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQ:AKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology. At the time of the merger, Akebia's lead product candidate, vadadustat, was an oral therapy in Phase 3 development and expected to become a new standard of care in the treatment of anemia due to chronic kidney disease ("CKD").
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets.
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The ...
Gainers Akebia Therapeutics (NASDAQ:AKBA) shares moved upwards by 3.31% to $3.43 during Thursday's after-market session. Akebia ...
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.20 per unit.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Moderna Inc (NASDAQ: MRNA) over Novavax, Inc. (NASDAQ: ...